摘要
目的探讨新辅助化疗联合腹腔镜下远端胃癌D2根治术治疗进展期胃癌的有效性分析。方法随机选取胃癌患者共60例进行分析研究,按照数字表法分为对照组(n=30)和研究组(n=30),对照组给予腹腔镜下远端胃癌D2根治术治疗,研究组给予新辅助化疗联合腹腔镜下远端胃癌D2根治术治疗,研究两组患者的T淋巴细胞亚群、免疫球蛋白、随访情况、治疗疗效以及并发症发生情况。结果研究组的CD3+、CD4+、CD4+/CD8+明显高于对照组(P<0.05),研究组的CD8+明显少于对照组(P<0.05);研究组的IgA、IgE水平明显少于对照组(P<0.05),研究组的IgG、IgM水平明显高于对照组(P<0.05);研究组的随访情况显著好于对照组(P<0.05);研究组的临床疗效显著好于对照组(P<0.05);研究组的并发症发生率显著低于对照组(P<0.05)。结论新辅助化疗联合腹腔镜下远端胃癌D2根治术治疗进展期胃癌具有显著的临床疗效,临床价值显著,安全性较高,该治疗方法值得在临床上进一步推广应用。
Objective To evaluate the efficacy of neoadjuvant chemotherapy combined with laparoscopic D2 radial resction of distl gastric cancer for advanced gastric cancer.Methods A total of 60 patients with gastric cancer were randomly selected and were divided into the control group(n=30)and the study group(n=30)according to the digital table method.The control group was treated with laparoscopic distal gastric cancer D2 radical operation,and the study group was treated with neoadjuvant chemotherapy combined with laparoscopic distal gastric cancer D2 radical operation.T lymphocyte subsets,immunoglobulin,follow-up,therapeutic efficacy and complications were studied in the 2 groups.Results The CD3+,CD4+and CD4+/CD8+of the study group were significantly higher than those of the control group,and the CD8+of the study group was significantly less than the control group.The level of IgA and IgE in the study group was significantly less than that of the control group.The IgG and IgM level of the study group was significantly higher than that of the control group.The follow-up of the study group was better than that of the control group;the clinical efficacy of the study group was significantly better than that of the control group;the incidence of complications in the study group was significantly lower than that of the control group.Conclusion The neoadjuvant chemotherapy combined with laparoscopic D2 radical gastrectomy for advanced gastric cancer has significant clinical efficacy,significant clinical value and high safety,which is worthy of further clinical application.
作者
杜记涛
万相斌
赵卫杰
陈广龙
李智
DU Jitao;WAN Xiangbin;ZHAO Weijie(Tumor Hospital Affiliated to Zhengzhou University,Zhengzhou,450003)
出处
《实用癌症杂志》
2019年第9期1497-1500,共4页
The Practical Journal of Cancer
基金
河南省科技攻关项目(编号:162102310317)
关键词
新辅助化疗
腹腔镜下远端胃癌D2根治术
进展期胃癌
Neoadjuvant chemotherapy
Laparoscopic distal gastrectomy for gastric cancer
D2
Advanced gastric cancer
